- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | FluoGuide A/S: FluoGuide includes first patient in phase II trial of FG001 for head and neck cancer | 71 | GlobeNewswire (Europe) | Copenhagen, Denmark - FluoGuide A/S ("FluoGuide" or the "Company"), a biotech company specializing in precision cancer surgery, is pleased to announce the inclusion of the first patient in its phase... ► Artikel lesen | |
| FLUOGUIDE Aktie jetzt für 0€ handeln | |||||
| 27.03. | Minutes from Annual General Meeting in FluoGuide A/S | 217 | ACCESS Newswire | COPENHAGEN, DENMARK / ACCESS Newswire / March 27, 2025 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company" held its annual general meeting on 27 March 2025.To the shareholders of FluoGuide A/S.The... ► Artikel lesen | |
| 12.03. | Notice of Annual General Meeting in FluoGuide A/S | 224 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / March 12, 2025 / FluoGuide A/S (STO:FLUO)The board of directors hereby convenes the Annual General Meeting of FluoGuide A/S, company registration (CVR) no. 39 29 64... ► Artikel lesen | |
| 27.02. | FluoGuide A/S Publishes Interim Report for the Period January - December 2024 | 198 | ACCESS Newswire | KØBENHAVN, DENMARK / ACCESS Newswire / February 27, 2025 / FluoGuide A/S (STO:FLUO) Copenhagen, Denmark, 27 February 2025 - Fluoguide A/S ("FluoGuide" or the "Company") today releases its results for... ► Artikel lesen | |
| 27.02. | FluoGuide A/S Publishes Year-End and Annual Report for the Fiscal Year 2024 | 220 | ACCESS Newswire | KØBENHAVN, DENMARK / ACCESS Newswire / February 27, 2025 / FluoGuide A/S (STO:FLUO) Copenhagen, Denmark, 27 February 2025 - FluoGuide A/S ("FluoGuide" or the "Company") hereby publishes its annual report... ► Artikel lesen | |
| 15.01. | FluoGuide A/S Receives Approval for Phase II Trial in Head and Neck Cancer | 265 | ACCESS Newswire | KØBENHAVN, DK / ACCESSWIRE / January 15, 2025 / FluoGuide A/S (STO:FLUO) Copenhagen, Denmark - FluoGuide A/S ("FluoGuide" or the "Company"), a biotech company specializing in precision cancer surgery... ► Artikel lesen | |
| 27.11.24 | FluoGuide A/S: FluoGuide A/S publishes interim report for the period January - September 2024 | 212 | GlobeNewswire (Europe) | Copenhagen, Denmark, 27 November 2024 - Fluoguide A/S ("FluoGuide" or the "Company") today releases its results for the period 1 January 2024 - 30 September 2024. The Q3 report is available as attached... ► Artikel lesen | |
| 29.08.24 | FluoGuide A/S: FluoGuide A/S publishes interim report for the period January - June 2024 | 102 | GlobeNewswire (Europe) | Copenhagen, Denmark, 29 August 2024 - FluoGuide A/S ("FluoGuide" or the "Company") today releases its results for the period 1 January - 30 June 2024. The Q2 report is available as an attached document... ► Artikel lesen | |
| 30.05.24 | FluoGuide A/S Publishes Interim Report for the Period January - March 2024 | 378 | ACCESS Newswire | KØBENHAVN, DK / ACCESSWIRE / May 30, 2024 / FluoGuide A/S (STO:FLUO) Copenhagen, Denmark, 30 May 2024 - FluoGuide A/S ("FluoGuide" or the "Company") today releases its results for the period 1 January... ► Artikel lesen | |
| 27.05.24 | FluoGuide A/S: FluoGuide Selects Laser System for Photothermal Cancer Therapy with FG001 | 563 | ACCESS Newswire | COPENHAGEN, DENMARK / ACCESSWIRE / May 27, 2024 / FluoGuide A/S (STO:FLUO) Copenhagen, Denmark - FluoGuide A/S ("FluoGuide" or the "Company"), a biotech company specializing in precision cancer surgery... ► Artikel lesen |
10 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PROCEPT BIOROBOTICS | 52,80 | -0,43 % | Piper Sandler maintains $100 target on Procept BioRobotics stock | ||
| GENEDX | 88,00 | -7,82 % | Secure and explainable: Sema4.ai enables AI agents for widespread enterprise deployment | ||
| ALIGNMENT HEALTHCARE | 17,460 | -4,28 % | Alignment Healthcare, Inc. - 8-K, Current Report | ||
| CASTLE BIOSCIENCES | 21,480 | -0,14 % | Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Results | FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced certain unaudited preliminary... ► Artikel lesen | |
| PROGYNY | 21,220 | -1,03 % | Progyny, Inc.: Progyny Names Healthcare Veterans Melissa Cummings as Chief Operating Officer and Geoffrey Clapp as Chief Product Officer | NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Progyny (Nasdaq: PGNY), a global leader in women's health and family building, today announced the appointments of Melissa Cummings as the company's first... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 15,520 | -6,51 % | BrightSpring Health Services, Inc. TANGIBLE EQUITY UNIT declares $0.843 dividend | ||
| NUTEX HEALTH | 148,00 | -0,67 % | Nutex Health files prospectus for secondary offering | ||
| AGILON HEALTH | 4,155 | +3,75 % | Where Agilon Health Stands With Analysts | ||
| ADAPTHEALTH | 7,140 | -8,34 % | AdaptHealth Corp. Announces Third Quarter 2024 Results | PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--AdaptHealth Corp. (NASDAQ: AHCO) ("AdaptHealth" or the "Company"), a national leader in providing patient-centered, healthcare-at-home solutions including... ► Artikel lesen | |
| PRIVIA HEALTH GROUP | 22,660 | -4,31 % | Assessing Privia Health Gr: Insights From 10 Financial Analysts | ||
| LIFESTANCE HEALTH GROUP | 6,145 | -8,28 % | LifeStance Health Group, Inc.: LifeStance Reports Fourth Quarter and Full Year 2024 Results | SCOTTSDALE, Ariz., Feb. 27, 2025 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation's largest providers of outpatient mental healthcare, today announced financial... ► Artikel lesen | |
| RESHAPE LIFESCIENCES | 0,392 | +26,41 % | ReShape Lifesciences skyrockets after receiving U.S. patent for diabetes neuromodulation technology | ||
| NANO-X IMAGING | 4,785 | -7,98 % | Nano-X Imaging LTD.: Nanox Receives FDA Clearance for General Use of New Imaging System, Nanox.ARC X | First FDA clearance for Nanox.ARC X to produce tomographic images for general use, including musculoskeletal, pulmonary, intra-abdominal and paranasal indicationsEnhanced imaging system features sleek... ► Artikel lesen | |
| CERIBELL | 14,915 | +0,47 % | CBLL Stock Falls Despite FDA Clearance for Pediatric Clarity Algorithm | ||
| RXSIGHT | 14,140 | -2,01 % | Piper Sandler sets RxSight stock target at $18, stays neutral |
Das Unternehmen FLUOGUIDE A/S kann der Branche Gesundheitswesen zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 3,170 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FLUOGUIDE A/S finden Sie auf Wallstreet Online.
